Anti-Human CEACAM5 Therapeutic Antibody (A5B7)

Figure 1 Mean (± SE) plasma concentration−time profiles of total platinum (s) and following iv bolus administration of cisplatin, CMdextran−cisplatin, A5B −CMdextran−cisplatin, A5B7−CMdextran−cisplatin, A5B7−CMdextran, and A5B7.

Mcintosh, D. P., Cooke, R. J., Mclachlan, A. J., Daley‐Yates, P. T., & Rowland, M. (1997). Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. Journal of pharmaceutical sciences, 86(12), 1478-1483.

Figure 2 Mean (± SE) concentration−time profiles of platinum (s) and ¹²⁵I (---)in kidney following iv bolus administration of cisplatin, CMdextran−cisplatin, A5B7−CMdextran−cisplatin, [¹²⁵I]A5B7−CMdextran−cisplatin, [¹²⁵I]A5B7−CMdextran, and A5B7.

Mcintosh, D. P., Cooke, R. J., Mclachlan, A. J., Daley‐Yates, P. T., & Rowland, M. (1997). Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. Journal of pharmaceutical sciences, 86(12), 1478-1483.